Shares of BioNTech SE (NASDAQ:BNTX) traded up 4.4% on Thursday . The company traded as high as $273.88 and last traded at $271.00. 16,905 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 2,197,576 shares. The stock had previously closed at $259.61.
BNTX has been the subject of a number of research reports. The Goldman Sachs Group assumed coverage on BioNTech in a report on Tuesday, May 18th. They set a “neutral” rating and a $173.00 target price for the company. Berenberg Bank set a $130.00 price objective on shares of BioNTech and gave the company a “buy” rating in a research note on Tuesday, April 6th. HC Wainwright reiterated a “hold” rating and issued a $194.00 price objective on shares of BioNTech in a research note on Tuesday. Bryan, Garnier & Co restated a “neutral” rating and set a $206.00 target price (up from $135.00) on shares of BioNTech in a research report on Monday, May 17th. Finally, Redburn Partners reaffirmed a “sell” rating and set a $146.00 price target on shares of BioNTech in a research report on Wednesday, June 16th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $169.83.
The firm has a 50-day moving average price of $217.35. The company has a current ratio of 2.70, a quick ratio of 2.58 and a debt-to-equity ratio of 0.09. The stock has a market cap of $66.49 billion, a price-to-earnings ratio of 45.47 and a beta of -1.58.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Baillie Gifford & Co. acquired a new position in shares of BioNTech during the 1st quarter worth about $735,723,000. Primecap Management Co. CA increased its stake in BioNTech by 4.2% during the 1st quarter. Primecap Management Co. CA now owns 4,821,718 shares of the company’s stock worth $526,483,000 after buying an additional 193,521 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of BioNTech by 31.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,074,906 shares of the company’s stock valued at $226,559,000 after acquiring an additional 500,085 shares during the last quarter. Artisan Partners Limited Partnership lifted its position in shares of BioNTech by 10.9% in the first quarter. Artisan Partners Limited Partnership now owns 1,582,256 shares of the company’s stock valued at $172,767,000 after acquiring an additional 155,682 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in shares of BioNTech by 11.1% in the first quarter. BlackRock Inc. now owns 742,858 shares of the company’s stock worth $81,112,000 after acquiring an additional 74,312 shares during the last quarter. Institutional investors and hedge funds own 12.42% of the company’s stock.
About BioNTech (NASDAQ:BNTX)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.
See Also: What is an Initial Coin Offering (ICO)?
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.